Lonza Biologics Inc.

Akadeum Life Sciences closed a $20 million+ financing round led by Michigan Capital Network to scale commercial operations and support customers entering clinical trials.

The antibody-drug conjugate (ADC) market in non-small-cell lung cancer is projected to grow at a 6.8% CAGR across seven major markets and exceed $3.9 billion by 2032.

Ethris has secured $5 million in funding from CEPI to advance the development of spray-dried RNA vaccines that remain stable at room temperature and are suitable for mucosal delivery.

Ethris and Lonza have formed a strategic partnership to develop spray-dried mRNA vaccines for respiratory diseases that remain stable at room temperature, eliminating cold chain requirements.

Swiss-based Debiopharm and French CRO Oncodesign Services have established a license agreement for AbYlink™, a regio-selective bioconjugation technology designed for therapeutic and non-invasive diagnostic applications.

Galapagos's lead CD19 CAR-T candidate GLPG5101 demonstrated compelling clinical results across three non-Hodgkin lymphoma indications, with complete response rates of 100% in MCL and 95% in MZL/FL.

Antibody-drug conjugates (ADCs) combine monoclonal antibody specificity with potent small molecule cytotoxicity, precisely delivering toxins to tumors and sparing normal tissues.

The global biotechnology market is expected to grow from USD 1.68 trillion in 2024 to USD 3.54 trillion by 2033, representing a CAGR of 9.18%, according to Cervicorn Consulting.

Pheast's lead drug candidate, PHST001, is set to enter first-in-human clinical trials, targeting the CD24 protein, a 'don't eat me' signal highly expressed in ovarian and breast cancers.

Acumen Pharmaceuticals and Lonza have broadened their partnership to include drug product manufacturing for sabirnetug, targeting early Alzheimer's disease.